{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:23:07Z","timestamp":1768342987205,"version":"3.49.0"},"reference-count":89,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After clinical trial failures in symptomatic Alzheimer's disease (AD), our field has moved to earlier intervention in cognitively normal individuals with biomarker evidence of AD. This offers potential for dementia prevention, but mainly low and variable rates of progression to AD dementia reduce the usefulness of trials\u2019 data in decision making by potential prescribers. With results from several Phase 3 secondary prevention studies anticipated within the next few years and the Food and Drug Administration's recent endorsement of amyloid beta as a surrogate outcome biomarker for AD clinical trials, it is time to question the clinical significance of changes in biomarkers, adequacy of current trial durations, and criteria for treatment success if cognitively unimpaired patients and their doctors are to meaningfully evaluate the potential value of new agents. We argue for a change of direction toward trial designs that can unambiguously inform clinical decision making about dementia risk and progression.<\/jats:p>","DOI":"10.1002\/alz.12788","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:03:48Z","timestamp":1664175828000},"page":"1073-1085","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?"],"prefix":"10.1002","volume":"19","author":[{"given":"Kathy Y.","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Psychiatry University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Thambisetty","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience Section Laboratory of Behavioral Neuroscience National Institute on Aging  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Psychiatry University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00636-z"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4668"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70223-4"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_2_7_6_1","unstructured":"Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease n.d. Accessed January 13 2022.https:\/\/www.cms.gov\/medicare\u2010coverage\u2010database\/view\/ncacal\u2010decision\u2010memo.aspx?proposed=Y&NCAId=305"},{"key":"e_1_2_7_7_1","unstructured":"Center for Drug Evaluation Research.FDA's Decision to Approve New Treatment for Alzheimer's Disease n.d. Accessed June 18 2021.https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fdas\u2010decision\u2010approve\u2010new\u2010treatment\u2010alzheimers\u2010disease"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.02.002"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_7_10_1","unstructured":"US Food and Drug Administration.Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry 2018. Accessed April 19 2021.https:\/\/www.fda.gov\/media\/110903\/download"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0891988710383571"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00066-1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.03.005"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70194-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/S135561771800022X"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.05.006"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-021-09478-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30371-5"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics1020011"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12179"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/349704a0"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0896-864"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0892"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.03.077"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4730"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180766"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010215492"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1151"},{"key":"e_1_2_7_31_1","first-page":"1","article-title":"The Alzheimer's disease drug development landscape","volume":"13","author":"Bokhoven P","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"e_1_2_7_32_1","unstructured":"Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed January 18 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008357?term=preclinical&recrs=abd&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=6"},{"key":"e_1_2_7_33_1","unstructured":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN\u2010TU001 \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed January 19 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01760005?term=preclinical+OR+prevent+OR+asymptomatic&recrs=abdf&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=4"},{"key":"e_1_2_7_34_1","unstructured":"AHEAD 3\u201045 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid n.d. Accessed January 18 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468659"},{"key":"e_1_2_7_35_1","unstructured":"A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER\u2010ALZ 3) n.d. Accessed January 18 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05026866?term=preclinical&recrs=abd&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=3"},{"key":"e_1_2_7_36_1","unstructured":"A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed March 7 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05256134?term=%E2%80%98preclinical%E2%80%99+OR+%E2%80%98prevent%27+OR+%E2%80%98asymptomatic%E2%80%99+OR+%27risk%E2%80%99&recrs=abdf&cond=Alzheimer+Disease&phase=2&draw=2&rank=2"},{"key":"e_1_2_7_37_1","unstructured":"Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed January 19 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02719327?term=preclinical&recrs=abdf&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=2"},{"key":"e_1_2_7_38_1","unstructured":"Risk Reduction for Alzheimer's Disease \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02913664"},{"key":"e_1_2_7_39_1","unstructured":"An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02569398?term=preclinical+OR+prevent+OR+asymptomatic+OR+risk&recrs=eghim&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=2"},{"key":"e_1_2_7_40_1","unstructured":"A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131453?term=preclinical+OR+prevent+OR+asymptomatic+OR+risk&recrs=eghim&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=4"},{"key":"e_1_2_7_41_1","unstructured":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04623242?term=preclinical+OR+prevent+OR+asymptomatic+OR+risk&recrs=eghim&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=3"},{"key":"e_1_2_7_42_1","unstructured":"A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02565511?term=preclinical+OR+prevent+OR+asymptomatic+OR+risk&recrs=eghim&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=5"},{"key":"e_1_2_7_43_1","unstructured":"Alzheimer's Disease Anti\u2010Inflammatory Prevention Trial (ADAPT) n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00007189?term=preclinical+OR+prevent+OR+asymptomatic+OR+risk&recrs=eghim&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=10"},{"key":"e_1_2_7_44_1","unstructured":"Alzheimer's Disease Prevention Trial n.d. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00000176?term=preclinical+OR+prevent+OR+asymptomatic+OR+risk&recrs=eghim&type=Intr&cond=Alzheimer+Disease&phase=2&draw=2&rank=6"},{"key":"e_1_2_7_45_1","unstructured":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset \u2010 Full Text View \u2010 ClinicalTrials.gov n.d. Accessed February 10 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01931566"},{"key":"e_1_2_7_46_1","first-page":"1","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","author":"Salloway S","year":"2021","journal-title":"Nat Med"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260269.93245.d2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00043-0"},{"key":"e_1_2_7_49_1","unstructured":"World Health Organization.Dementia: a public health priority.World Health Organization.2012.https:\/\/apps.who.int\/iris\/handle\/10665\/75263"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0116-6"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n156"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.183"},{"key":"e_1_2_7_54_1","article-title":"Clinical and biomarker trajectories in sporadic Alzheimer's disease: a longitudinal study","volume":"12","author":"Wang H\u2010F","year":"2020","journal-title":"Alzheimers Dement"},{"key":"e_1_2_7_55_1","article-title":"Composite cognitive and functional measures for early stage Alzheimer's disease trials","volume":"12","author":"Schneider LS","year":"2020","journal-title":"Alzheimers Dement"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007831"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000055"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25395"},{"key":"e_1_2_7_59_1","unstructured":"LinGA WhittingtonMD SynnottPG et al.Aducanumab for Alzheimer's Disease: Effectiveness and Value; Final Evidence Report and Meeting Summary.Institute for Clinical and Economic Review August 5 2021.https:\/\/icer.org\/assessment\/alzheimers\u2010disease\u20102021\/"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6669"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy150"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2031"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09989"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2014.12.015"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007901"},{"key":"e_1_2_7_67_1","first-page":"e662","article-title":"Association of \u03b2\u2010amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"Kall LM","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0194"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435556.21319.e4"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00621-6"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.09.030"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318232ac1a"},{"key":"e_1_2_7_73_1","unstructured":"US Food and Drug Administration.Updated full prescribing information for ADUHELM 2021.https:\/\/www.biogencdn.com\/us\/aduhelm\u2010pi.pdf"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30029-2"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5216"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.08.017"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00949-7"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22354-2"},{"key":"e_1_2_7_80_1","article-title":"Digital biomarker\u2010based individualized prognosis for people at risk of dementia","volume":"12","author":"Buegler M","year":"2020","journal-title":"Alzheimers Dement"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102199"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0"},{"key":"e_1_2_7_83_1","doi-asserted-by":"crossref","unstructured":"OssenkoppeleR BinetteAP GrootC et al.Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline? bioRxiv2022.https:\/\/doi.org\/10.1101\/2022.05.23.22275241","DOI":"10.1101\/2022.05.23.22275241"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2379"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21487"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm213"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12959"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab452"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00557-x"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.12788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.12788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:59:17Z","timestamp":1759928357000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.12788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/alz.12788"],"URL":"https:\/\/doi.org\/10.1002\/alz.12788","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"2022-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}